Acidum p-aminobensoicum

Overdose

Accidental ingestion does not pose a risk of unwanted side effects.

Contraindications

Hypersensitivity to the components of the drug. To date, data from clinical trials regarding the use of the drug during pregnancy, lactation, and in children are not available. However, the drug can be used if the intended benefit exceeds the possible risk.

Incompatibilities

In combination with modified nucleosides (acyclovir, ganciclovir, fludarabine phosphate, etc.) and antibiotics, the therapeutic effect is enhanced. Do not use simultaneously with sulfa drugs (sulfacetamide), with Encada for local use.

Pharmaceutical form

Substance-powder

Undesirable effects

Rarely conjunctival hyperemia, local allergic reactions.

Therapeutic indications

Viral conjunctivitis, keratoconjunctivitis, keratouveitis caused by Herpes simplex, Herpes zoster, adenovirus, keratopathies of infectious, post-traumatic and post-operative genesis, dystrophic diseases of the retina and cornea, burns and eye injuries, discomfort associated with eye strain and fatigue, including when wearing contact lenses.

Pharmacotherapeutic group

  • Other immunomodulators
  • Antiviral drugs (excluding HIV)

Pharmacokinetic properties

When administered topically, paraaminobenzoic acid is rapidly absorbed and has a therapeutic effect.

Name of the medicinal product

Acidum p-aminobensoicum

Special precautions for storage

In a dry place, protected from light, at a temperature not exceeding 30 °C.

Keep out of reach of children.

Shelf life of the drug P-aminobenzoic acid5 лет.

Do not use after the expiration date indicated on the package.

Qualitative and quantitative composition

Aminobenzoic Acid

Dosage (Posology) and method of administration

Local: instill in the conjunctival sac 1-2 drops 3-8 times a day. After clinical recovery, instillation is continued for 2 drops 3 times a day for 7 days.

Subconjunctival, parabulbar, retrobulbar: injections of 0.3-0.5 ml. The course of 3-15 injections. For superficial forms of herpetic keratitis, injections are made after 1 day or after 2-3 days in combination with instillations of 2 drops 4-8 times a day, depending on the course of the disease. In deep forms of herpetic keratitis, injections are first carried out 1 time daily, then after 2-3 days in combination with instillation of 2 drops 4-8 times, depending on the severity and dynamics of the disease. After clinical recovery, in both forms of the disease, instillation is continued for 2 drops per day for 7-10 days.

Privateline: for retinal dystrophy-injections of 1 ml, the course of treatment — 10 injections.